In vitro prolonged gastric residence and sustained release of atenolol using novel clay polymer nanocomposite
Source abstract
Abstract
Abstract Atenolol (ATN) is a widely prescribed drug for the treatment of hypertension. Due to short biological half life, low oral bioavailability and poor absorption from the lower gastrointestinal tract, high doses are required to maintain its therapeutic level in the blood plasma which has undesirable side effects. It seems that an increase in gastric residence time may increase the extent of absorption and bioavailability of the ATN. Therefore, to overcome the drawbacks associated with conventional oral delivery of ATN, a new drug delivery vehicle is required. The purpose of the present research was to develop montmorillonite (Mt)-poly lactic-co-glycolic acid (PLGA) nanocomposites as sustained release oral delivery vehicle for ATN. The Mt–PLGA nanocomposites were prepared by w/o/w double emulsion solvent evaporation method by varying the ATN to Mt ratio at three levels using Pluronic F68 and PLGA as stabilizing agent and matrix material respectively. Effects of these compositions on interlayer spacing of Mt–PLGA nanocomposites, particle size, morphology and in vitro drug release were evaluated. The in vitro release behavior of ATN from Mt–ATN–PLGA nanocomposites was found to be pH dependent and sustained as compared to ATN–PLGA nanoparticles, pure ATN and commercial formulation of Atenolol “ATEN-25” over a period of 24 h. The developed clay polymer nanocomposites (CPN) show promising ability to prolong the gastric residence time of ATN and suggest the possibility of designing the sustained release formulations with improved bioavailability and patient compliance.
Source: openaire · Quality: candidate unverified · Source record ↗
Research context
OpenAlex topics: Polymer Nanocomposites and Properties · Drug Solubulity and Delivery Systems · Hydrogels: synthesis, properties, applications
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
References (79)
Show source-provided references
1. Sol–gel transitions of sodium montmorillonite dispersions10.1016/S0169-1317(99)00040-X ↗
2. Amphiphilic block copolymers for drug delivery10.1002/jps.10397 ↗
3. Use of clays as drug delivery systems: possibilities and limitations10.1016/j.clay.2006.06.015 ↗
4. Interactions between poloxamers in aqueous solutions: micellization and gelation studied by differential scanning calorimetry, small angle X-ray scattering, and rheology10.1021/la062622p ↗
5. Soo-Jin Choi10.1007/s13273-012-0012-x ↗
6. Barhate · Der Pharm. Lett. · 2011 · 3 · 34
7. A new type of cardioselective adrenoceptive blocking drug
8. Bergaya · 2006
9. Development and in vitro-in vivo evaluation of oral drug delivery system of acyclovir loaded PLGA nanoparticles
10. Validated HPLC method for simultaneous quantitation of amlodipine besylate, atenolol, and aspirin in bulk drug and formulation
11. Montmorillonite nanodevices for the colon metronidazole delivery10.1016/j.ijpharm.2013.09.017 ↗
12. Floating matrix dosage form for propranolol hydrochloride based on gas formation technique: development and in vitro evaluation10.3797/scipharm.0909-02 ↗
13. Tramadol hydrochloride/montmorillonite composite: preparation and controlled drug release10.1016/j.clay.2010.04.011 ↗
14. Gelatin blended with nanoparticle cloisite30B (Mt) for control drug delivery of anticancer drug paclitaxel
15. Cell proliferation and controlled drug release studies of nanohybrids based on chitosan-g-lactic acid and montmorillonite10.1016/j.actbio.2008.08.007 ↗
16. Formulation and evaluation of floating matrix tablet of atenolol for gastro-retentive drug delivery, Int
17. Polymers derived from Xanthomonas campesteris and Cyamopsis tetragonolobus use as retardant materials for the formulation of sustained release floating matrix tablet of atenolol10.1016/j.ijbiomac.2014.01.049 ↗
18. Poly (D, L-lactide-co-glycolide)/montmorillonite nanoparticles for oral delivery of anticancer drugs10.1016/j.biomaterials.2005.03.021 ↗
19. Poly(lactide)-vitamin E derivative/montmorillonite nanoparticle formulations for the oral delivery of docetaxel10.1016/j.biomaterials.2009.02.045 ↗
20. Drug therapy: Atenolol and Timolol, two new systemic β-adrenoceptor antagonists10.1056/NEJM198206173062404 ↗
21. Preparation and characterization of hybrid organic–inorganic composite materials using the amphoteric property of amino acids: amino acid intercalated layered double hydroxide and montmorillonite10.1021/ic981176t ↗
22. The manufacturing techniques of various drug loaded biodegradable poly(lactide-co-glycolide) (PLGA) devices10.1016/S0142-9612(00)00115-0 ↗
23. Montmorillonite–PLGA nanocomposites as an oral extended drug delivery vehicle for venlafaxine hydrochloride10.1016/j.clay.2014.06.006 ↗
24. Naturally occurring clay, montmorillonite, as a drug delivery vehicle for in vitro extended release of venlafaxine hydrochloride
25. Proton saturation and rheological properties of smectite dispersions10.1016/S0169-1317(01)00051-5 ↗
26. Intercalation of amido cationic drug with montmorillonite
27. Pluronic block copolymers as novel polymer therapeutics for drug and gene delivery10.1016/S0168-3659(02)00009-3 ↗
28. Synthesis and characterization of biodegradable clay–polymer nanocomposites for oral sustained release of anti-inflammatory drug
29. In vitro release of sodium diclofenac from poloxamer 188 modified montmorillonite as an oral drug delivery vehicle
30. Diclofenac sodium adsorption onto montmorillonite: adsorption equilibrium studies and drug release kinetics10.1260/0263-6174.32.5.365 ↗
31. Controlled release of atenolol from the ethylene-vinyl acetate matrix10.1016/j.ijpharm.2003.12.004 ↗
32. Intercalating amino acid guests into montmorillonite host10.1016/S0022-2860(03)00109-1 ↗
33. Development and evaluation of regioselective bilayer floating tablets of Atenolol and Lovastatin for biphasic release profile
34. Development and validation of a novel isocratic RP-HPLC method for simultaneous determination of atenolol and aspirin in fixed dose combinations
35. Design, development, optimization and evaluation of gastro-retentive floating tablets of atenolol
36. Lakshmi · Appl. Clay Sci. · 2010 · 48 · 58910.1016/j.clay.2010.03.008 ↗
37. Smectites–polymer nanocomposites (Chapter 13.1)
38. Toxicity assessment of montmorillonite as a drug carrier for pharmaceutical applications: yeast and rats model10.4015/S1016237205000111 ↗
39. A study of purified montmorillonite intercalated with 5-fluorouracil as drug carrier10.1016/S0142-9612(01)00325-8 ↗
40. Intercalation and exfoliation: a review on morphology of polymer nanocomposites reinforced by inorganic layer structures materials and manufacturing processes
41. Majid · Eur. J. Cardiol. · 1979 · 9 · 419
42. Formulation and development of extended release floating tablet of atenolol
43. Curcumin loaded-PLGA nanoparticles conjugated with Tet-1 peptide for potential use in Alzheimer’s disease10.1371/journal.pone.0032616 ↗
44. In vitro degradation of nanoparticles prepared from polymers based on DL-lactide, glycolide and poly(ethylene oxide)10.1016/j.jconrel.2004.09.008 ↗
45. PLGA-based nanoparticles as cancer drug delivery systems10.7314/APJCP.2014.15.2.517 ↗
46. Olad · 2011 · 113
47. Predictors of glass transition in the biodegradable polylactide and poly-lactide-co-glycolide polymers10.1002/app.22135 ↗
48. Polymer nanotechnology: nanocomposites10.1016/j.polymer.2008.04.017 ↗
49. Influence of anions on the rheological properties of clay mineral dispersions10.1016/S0169-1317(01)00052-7 ↗
50. Thermoanalytical study of atenolol and commercial tablets
51. Mechanical and drug release properties of atenolol–carbopol hydrophilic matrix tablets10.1016/0168-3659(91)90145-4 ↗
52. Nano-clays and drug delivery system: an overview
53. A rheological approach to the stability of humic acid/clay colloidal suspensions10.1007/s00397-002-0266-7 ↗
54. Zinc cross-linked hydroxamated alginates for pulsed drug release10.4103/2230-973X.121292 ↗
55. The systems containing clays and clay minerals from modified drug release: a review10.1016/j.colsurfb.2012.10.068 ↗
56. Comparative pharmacokinetic study of a floating multiple-unit capsule, a high-density multiple-unit capsule and an immediate-release tablet containing 25mg atenolol10.1016/S0031-6865(97)00050-2 ↗
57. Formulation and evaluation of nanoparticles containing atenolol by ionic gelation technique
58. Atenolol gastrointestinal therapeutic system: optimization of formulation variables using response surface methodology10.1016/S0168-3659(96)01553-2 ↗
59. A review of block polymer surfactants10.1007/BF02894385 ↗
60. In vitro sustained delivery of atenolol, an antihypertensive drug using naturally occurring clay mineral montmorillonite as a carrier
61. Clay–polymer nanocomposites as a novel drug carrier: synthesis, characterization and controlled release study of propranolol hydrochloride10.1016/j.clay.2013.06.009 ↗
62. MMT–PLGA nanocomposites as an oral and controlled release carrier for 5-fluorouracil: a novel approach
63. Organoclay Pluronic F68–montmorillonite, as a sustained release drug delivery vehicle for propranolol hydrochloride
64. Formulation of atenolol mucoadhesive microspheres for nasal delivery by spray drying technique: in vitro/ex vivo evaluation
65. Study of some volatile compounds evolved from the thermal decomposition of atenolol
66. Formulation and optimization of controlled release mucoadhesive tablets of atenolol using response surface methodology10.1208/pt070103 ↗
67. Oral sustained delivery of atenolol from floating matrix tablets, formulation and in vitro evaluation
68. Nano clay drug delivery system
69. Preparation and evaluation of atenolol floating beads as a controlled delivery system10.31351/vol20iss1pp70-80 ↗
70. Colloidal behavior of aqueous montmorillonite suspensions: the specific role of pH in the presence of indifferent electrolytes10.1016/j.clay.2004.01.001 ↗
71. Long-term stability characterization of a controlled release gastro-intestinal therapeutic system coated with a cellulose acetate pseudolatex
72. Atenolol release from hydrophilic matrix tablets with hydroxypropyl methylcellulose (HPMC) mixtures as gelling agent: effects of the viscosity of the HPMC mixture10.1016/0928-0987(95)00030-5 ↗
73. Biopolymer clay nanocomposites for controlled drug delivery10.1179/174328408X341708 ↗
74. Wander · Suppl. JAPI · 2009 · 57 · 13
75. Biopolymer/montmorillonite nanocomposite: preparation drug-controlled release property and cytotoxicity
76. Controlled and extended drug release behavior of chitosan-based nanoparticle carrier10.1016/j.actbio.2009.08.027 ↗
77. Intercalation of poly(ethylene-oxides) in montmorillonite: tailor-made nanocontainers for drug delivery systems10.1016/j.clay.2010.08.009 ↗
78. Poly(trimethylene carbonate) and monomethoxy poly(ethylene glycol)-block-poly(trimethylene carbonate) nanoparticles for the controlled release of dexamethasone10.1016/j.jconrel.2005.12.001 ↗
79. Curcumin loaded mixed micelles composed of pluronic P123 and F68: preparation, optimization and in vitro characterization`10.1016/j.colsurfb.2012.04.017 ↗